^
BRAF V600E
|
Thyroid Gland Anaplastic Carcinoma
|
BRAF V600E
|
Thyroid Gland Anaplastic Carcinoma
|
trametinib + dabrafenib Sensitive: A1 - Approval
Ann Oncol - 1 week
|
trametinib + dabrafenib Sensitive: A1 - Approval
Ann Oncol - 1 week
|
No biomarker
|
Thyroid Gland Medullary Carcinoma
|
No biomarker
|
Thyroid Gland Medullary Carcinoma
|
cabozantinib capsule Sensitive: A1 - Approval
|
cabozantinib capsule Sensitive: A1 - Approval
|
RET fusion
|
Thyroid Gland Carcinoma
|
RET fusion
|
Thyroid Gland Carcinoma
|
pralsetinib Sensitive: A1 - Approval
|
pralsetinib Sensitive: A1 - Approval
|
No biomarker
|
Thyroid Gland Carcinoma
|
No biomarker
|
Thyroid Gland Carcinoma
|
cabozantinib tablet Sensitive: A1 - Approval
|
cabozantinib tablet Sensitive: A1 - Approval
|
RET mutation
|
Thyroid Gland Medullary Carcinoma
|
RET mutation
|
Thyroid Gland Medullary Carcinoma
|
selpercatinib Sensitive: A1 - Approval
|
selpercatinib Sensitive: A1 - Approval
|
RET fusion
|
Thyroid Gland Carcinoma
|
RET fusion
|
Thyroid Gland Carcinoma
|
selpercatinib Sensitive: A1 - Approval
|
selpercatinib Sensitive: A1 - Approval
|
No biomarker
|
Thyroid Gland Hurthle Cell Carcinoma
|
No biomarker
|
Thyroid Gland Hurthle Cell Carcinoma
|
sorafenib Sensitive: A1 - Approval
|
sorafenib Sensitive: A1 - Approval
|
No biomarker
|
Thyroid Gland Follicular Carcinoma
|
No biomarker
|
Thyroid Gland Follicular Carcinoma
|
sorafenib Sensitive: A1 - Approval
|
sorafenib Sensitive: A1 - Approval
|
No biomarker
|
Thyroid Gland Papillary Carcinoma
|
No biomarker
|
Thyroid Gland Papillary Carcinoma
|
sorafenib Sensitive: A1 - Approval
|
sorafenib Sensitive: A1 - Approval
|
No biomarker
|
Thyroid Gland Follicular Carcinoma
|
No biomarker
|
Thyroid Gland Follicular Carcinoma
|
lenvatinib Sensitive: A1 - Approval
|
lenvatinib Sensitive: A1 - Approval
|
No biomarker
|
Thyroid Gland Hurthle Cell Carcinoma
|
No biomarker
|
Thyroid Gland Hurthle Cell Carcinoma
|
lenvatinib Sensitive: A1 - Approval
|
lenvatinib Sensitive: A1 - Approval
|
No biomarker
|
Thyroid Gland Papillary Carcinoma
|
No biomarker
|
Thyroid Gland Papillary Carcinoma
|
lenvatinib Sensitive: A1 - Approval
|
lenvatinib Sensitive: A1 - Approval
|
No biomarker
|
Thyroid Gland Medullary Carcinoma
|
No biomarker
|
Thyroid Gland Medullary Carcinoma
|
vandetanib Sensitive: A1 - Approval
|
vandetanib Sensitive: A1 - Approval
|
RET mutation
|
Thyroid Gland Medullary Carcinoma
|
RET mutation
|
Thyroid Gland Medullary Carcinoma
|
pralsetinib Sensitive: A1 - Approval
|
pralsetinib Sensitive: A1 - Approval
|
BRAF V600E
|
Thyroid Gland Anaplastic Carcinoma
|
BRAF V600E
|
Thyroid Gland Anaplastic Carcinoma
|
dabrafenib Sensitive: A1 - Approval
|
dabrafenib Sensitive: A1 - Approval
|
No biomarker
|
Thyroid Gland Carcinoma
|
No biomarker
|
Thyroid Gland Carcinoma
|
lenvatinib Sensitive: A1 - Approval
|
lenvatinib Sensitive: A1 - Approval
|
HER-2 positive
|
Salivary Gland Cancer
|
HER-2 positive
|
Salivary Gland Cancer
|
trastuzumab Sensitive: A1 - Approval
|
trastuzumab Sensitive: A1 - Approval
|
No biomarker
|
Head and Neck Cancer
|
No biomarker
|
Head and Neck Cancer
|
cetuximab sarotalocan Sensitive: A1 - Approval
|
cetuximab sarotalocan Sensitive: A1 - Approval
|
No biomarker
|
Nasopharyngeal Carcinoma
|
No biomarker
|
Nasopharyngeal Carcinoma
|
toripalimab Sensitive: A1 - Approval
|
toripalimab Sensitive: A1 - Approval
|
NTRK1 fusion
|
Thyroid Gland Follicular Carcinoma
|
NTRK1 fusion
|
Thyroid Gland Follicular Carcinoma
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
No biomarker
|
Thyroid Gland Medullary Carcinoma
|
No biomarker
|
Thyroid Gland Medullary Carcinoma
|
dacarbazine Sensitive: A2 - Guideline
|
dacarbazine Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Thyroid Gland Follicular Carcinoma
|
NTRK2 fusion
|
Thyroid Gland Follicular Carcinoma
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK3 fusion
|
Thyroid Gland Follicular Carcinoma
|
NTRK3 fusion
|
Thyroid Gland Follicular Carcinoma
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK1 fusion
|
Thyroid Gland Hurthle Cell Carcinoma
|
NTRK1 fusion
|
Thyroid Gland Hurthle Cell Carcinoma
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Thyroid Gland Hurthle Cell Carcinoma
|
NTRK2 fusion
|
Thyroid Gland Hurthle Cell Carcinoma
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK1 fusion
|
Thyroid Gland Follicular Carcinoma
|
NTRK1 fusion
|
Thyroid Gland Follicular Carcinoma
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Thyroid Gland Follicular Carcinoma
|
NTRK2 fusion
|
Thyroid Gland Follicular Carcinoma
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK3 fusion
|
Thyroid Gland Follicular Carcinoma
|
NTRK3 fusion
|
Thyroid Gland Follicular Carcinoma
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
No biomarker
|
Oropharyngeal Cancer
|
No biomarker
|
Oropharyngeal Cancer
|
TPF Sensitive: A2 - Guideline
|
TPF Sensitive: A2 - Guideline
|
No biomarker
|
Oral Cancer
|
No biomarker
|
Oral Cancer
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
PD-L1 expression
|
Oral Cancer
|
PD-L1 expression
|
Oral Cancer
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
No biomarker
|
Oral Cancer
|
No biomarker
|
Oral Cancer
|
cisplatin + paclitaxel + 5-fluorouracil Sensitive: A2 - Guideline
|
cisplatin + paclitaxel + 5-fluorouracil Sensitive: A2 - Guideline
|
No biomarker
|
Oral Cancer
|
No biomarker
|
Oral Cancer
|
paclitaxel Sensitive: A2 - Guideline
|
paclitaxel Sensitive: A2 - Guideline
|
No biomarker
|
Oral Cancer
|
No biomarker
|
Oral Cancer
|
nivolumab Sensitive: A2 - Guideline
|
nivolumab Sensitive: A2 - Guideline
|
No biomarker
|
Oral Cancer
|
No biomarker
|
Oral Cancer
|
methotrexate Sensitive: A2 - Guideline
|
methotrexate Sensitive: A2 - Guideline
|
No biomarker
|
Oral Cancer
|
No biomarker
|
Oral Cancer
|
docetaxel Sensitive: A2 - Guideline
|
docetaxel Sensitive: A2 - Guideline
|
No biomarker
|
Oral Cancer
|
No biomarker
|
Oral Cancer
|
cisplatin + docetaxel Sensitive: A2 - Guideline
|
cisplatin + docetaxel Sensitive: A2 - Guideline
|
No biomarker
|
Oral Cancer
|
No biomarker
|
Oral Cancer
|
carboplatin + paclitaxel Sensitive: A2 - Guideline
|
carboplatin + paclitaxel Sensitive: A2 - Guideline
|
No biomarker
|
Oral Cancer
|
No biomarker
|
Oral Cancer
|
cetuximab Sensitive: A2 - Guideline
|
cetuximab Sensitive: A2 - Guideline
|
No biomarker
|
Oral Cancer
|
No biomarker
|
Oral Cancer
|
capecitabine Sensitive: A2 - Guideline
|
capecitabine Sensitive: A2 - Guideline
|
No biomarker
|
Oral Cancer
|
No biomarker
|
Oral Cancer
|
afatinib Sensitive: A2 - Guideline
|
afatinib Sensitive: A2 - Guideline
|
No biomarker
|
Oral Cancer
|
No biomarker
|
Oral Cancer
|
5-fluorouracil Sensitive: A2 - Guideline
|
5-fluorouracil Sensitive: A2 - Guideline
|
No biomarker
|
Oral Cancer
|
No biomarker
|
Oral Cancer
|
cisplatin Sensitive: A2 - Guideline
|
cisplatin Sensitive: A2 - Guideline
|
No biomarker
|
Oral Cancer
|
No biomarker
|
Oral Cancer
|
cisplatin + 5-fluorouracil + docetaxel Sensitive: A2 - Guideline
|
cisplatin + 5-fluorouracil + docetaxel Sensitive: A2 - Guideline
|
No biomarker
|
Oral Cancer
|
No biomarker
|
Oral Cancer
|
cisplatin + paclitaxel Sensitive: A2 - Guideline
|
cisplatin + paclitaxel Sensitive: A2 - Guideline
|
No biomarker
|
Oropharyngeal Cancer
|
No biomarker
|
Oropharyngeal Cancer
|
cisplatin + paclitaxel Sensitive: A2 - Guideline
|
cisplatin + paclitaxel Sensitive: A2 - Guideline
|
No biomarker
|
Oropharyngeal Cancer
|
No biomarker
|
Oropharyngeal Cancer
|
afatinib Sensitive: A2 - Guideline
|
afatinib Sensitive: A2 - Guideline
|
No biomarker
|
Oropharyngeal Cancer
|
No biomarker
|
Oropharyngeal Cancer
|
capecitabine Sensitive: A2 - Guideline
|
capecitabine Sensitive: A2 - Guideline
|
No biomarker
|
Oropharyngeal Cancer
|
No biomarker
|
Oropharyngeal Cancer
|
methotrexate Sensitive: A2 - Guideline
|
methotrexate Sensitive: A2 - Guideline
|
No biomarker
|
Oropharyngeal Cancer
|
No biomarker
|
Oropharyngeal Cancer
|
5-fluorouracil Sensitive: A2 - Guideline
|
5-fluorouracil Sensitive: A2 - Guideline
|
No biomarker
|
Oropharyngeal Cancer
|
No biomarker
|
Oropharyngeal Cancer
|
docetaxel Sensitive: A2 - Guideline
|
docetaxel Sensitive: A2 - Guideline
|
No biomarker
|
Oropharyngeal Cancer
|
No biomarker
|
Oropharyngeal Cancer
|
paclitaxel Sensitive: A2 - Guideline
|
paclitaxel Sensitive: A2 - Guideline
|
No biomarker
|
Oropharyngeal Cancer
|
No biomarker
|
Oropharyngeal Cancer
|
carboplatin Sensitive: A2 - Guideline
|
carboplatin Sensitive: A2 - Guideline
|
No biomarker
|
Oropharyngeal Cancer
|
No biomarker
|
Oropharyngeal Cancer
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
No biomarker
|
Oropharyngeal Cancer
|
No biomarker
|
Oropharyngeal Cancer
|
cetuximab Sensitive: A2 - Guideline
|
cetuximab Sensitive: A2 - Guideline
|
No biomarker
|
Oropharyngeal Cancer
|
No biomarker
|
Oropharyngeal Cancer
|
carboplatin + paclitaxel Sensitive: A2 - Guideline
|
carboplatin + paclitaxel Sensitive: A2 - Guideline
|
No biomarker
|
Oropharyngeal Cancer
|
No biomarker
|
Oropharyngeal Cancer
|
cisplatin + docetaxel Sensitive: A2 - Guideline
|
cisplatin + docetaxel Sensitive: A2 - Guideline
|
No biomarker
|
Oropharyngeal Cancer
|
No biomarker
|
Oropharyngeal Cancer
|
nivolumab Sensitive: A2 - Guideline
|
nivolumab Sensitive: A2 - Guideline
|
PD-L1 expression
|
Oropharyngeal Cancer
|
PD-L1 expression
|
Oropharyngeal Cancer
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
No biomarker
|
Oropharyngeal Cancer
|
No biomarker
|
Oropharyngeal Cancer
|
cisplatin + paclitaxel + 5-fluorouracil Sensitive: A2 - Guideline
|
cisplatin + paclitaxel + 5-fluorouracil Sensitive: A2 - Guideline
|
No biomarker
|
Oral Cancer
|
No biomarker
|
Oral Cancer
|
cisplatin + 5-fluorouracil Sensitive: A2 - Guideline
|
cisplatin + 5-fluorouracil Sensitive: A2 - Guideline
|
No biomarker
|
Oral Cancer
|
No biomarker
|
Oral Cancer
|
5-fluorouracil + hydroxyurea Sensitive: A2 - Guideline
|
5-fluorouracil + hydroxyurea Sensitive: A2 - Guideline
|
No biomarker
|
Oral Cancer
|
No biomarker
|
Oral Cancer
|
carboplatin + 5-fluorouracil Sensitive: A2 - Guideline
|
carboplatin + 5-fluorouracil Sensitive: A2 - Guideline
|
No biomarker
|
Oropharyngeal Cancer
|
No biomarker
|
Oropharyngeal Cancer
|
cisplatin + 5-fluorouracil Sensitive: A2 - Guideline
|
cisplatin + 5-fluorouracil Sensitive: A2 - Guideline
|
No biomarker
|
Oropharyngeal Cancer
|
No biomarker
|
Oropharyngeal Cancer
|
5-fluorouracil + hydroxyurea Sensitive: A2 - Guideline
|
5-fluorouracil + hydroxyurea Sensitive: A2 - Guideline
|
No biomarker
|
Oropharyngeal Cancer
|
No biomarker
|
Oropharyngeal Cancer
|
carboplatin + 5-fluorouracil Sensitive: A2 - Guideline
|
carboplatin + 5-fluorouracil Sensitive: A2 - Guideline
|
No biomarker
|
Oropharyngeal Cancer
|
No biomarker
|
Oropharyngeal Cancer
|
cisplatin Sensitive: A2 - Guideline
|
cisplatin Sensitive: A2 - Guideline
|
No biomarker
|
Nasopharyngeal Carcinoma
|
No biomarker
|
Nasopharyngeal Carcinoma
|
GC Sensitive: A2 - Guideline
|
GC Sensitive: A2 - Guideline
|
No biomarker
|
Nasopharyngeal Carcinoma
|
No biomarker
|
Nasopharyngeal Carcinoma
|
carboplatin + paclitaxel Sensitive: A2 - Guideline
|
carboplatin + paclitaxel Sensitive: A2 - Guideline
|
No biomarker
|
Maxillary Sinus Carcinoma
|
No biomarker
|
Maxillary Sinus Carcinoma
|
VC Sensitive: A2 - Guideline
|
VC Sensitive: A2 - Guideline
|
No biomarker
|
Maxillary Sinus Carcinoma
|
No biomarker
|
Maxillary Sinus Carcinoma
|
EP Sensitive: A2 - Guideline
|
EP Sensitive: A2 - Guideline
|
No biomarker
|
Maxillary Sinus Carcinoma
|
No biomarker
|
Maxillary Sinus Carcinoma
|
CAV Sensitive: A2 - Guideline
|
CAV Sensitive: A2 - Guideline
|
No biomarker
|
Nasopharyngeal Carcinoma
|
No biomarker
|
Nasopharyngeal Carcinoma
|
DP Sensitive: A2 - Guideline
|
DP Sensitive: A2 - Guideline
|
No biomarker
|
Nasopharyngeal Carcinoma
|
No biomarker
|
Nasopharyngeal Carcinoma
|
TPF Sensitive: A2 - Guideline
|
TPF Sensitive: A2 - Guideline
|
No biomarker
|
Thyroid Gland Anaplastic Carcinoma
|
No biomarker
|
Thyroid Gland Anaplastic Carcinoma
|
CaT Sensitive: A2 - Guideline
|
CaT Sensitive: A2 - Guideline
|
MSI-H/dMMR
|
Maxillary Sinus Carcinoma
|
MSI-H/dMMR
|
Maxillary Sinus Carcinoma
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
No biomarker
|
Nasopharyngeal Carcinoma
|
No biomarker
|
Nasopharyngeal Carcinoma
|
cetuximab Sensitive: A2 - Guideline
|
cetuximab Sensitive: A2 - Guideline
|
No biomarker
|
Nasopharyngeal Carcinoma
|
No biomarker
|
Nasopharyngeal Carcinoma
|
oxaliplatin Sensitive: A2 - Guideline
|
oxaliplatin Sensitive: A2 - Guideline
|
No biomarker
|
Nasopharyngeal Carcinoma
|
No biomarker
|
Nasopharyngeal Carcinoma
|
doxorubicin hydrochloride Sensitive: A2 - Guideline
|
doxorubicin hydrochloride Sensitive: A2 - Guideline
|
No biomarker
|
Nasopharyngeal Carcinoma
|
No biomarker
|
Nasopharyngeal Carcinoma
|
ifosfamide Sensitive: A2 - Guideline
|
ifosfamide Sensitive: A2 - Guideline
|
No biomarker
|
Nasopharyngeal Carcinoma
|
No biomarker
|
Nasopharyngeal Carcinoma
|
vinorelbine tartrate Sensitive: A2 - Guideline
|
vinorelbine tartrate Sensitive: A2 - Guideline
|
No biomarker
|
Nasopharyngeal Carcinoma
|
No biomarker
|
Nasopharyngeal Carcinoma
|
irinotecan Sensitive: A2 - Guideline
|
irinotecan Sensitive: A2 - Guideline
|
No biomarker
|
Nasopharyngeal Carcinoma
|
No biomarker
|
Nasopharyngeal Carcinoma
|
capecitabine Sensitive: A2 - Guideline
|
capecitabine Sensitive: A2 - Guideline
|
No biomarker
|
Nasopharyngeal Carcinoma
|
No biomarker
|
Nasopharyngeal Carcinoma
|
5-fluorouracil Sensitive: A2 - Guideline
|
5-fluorouracil Sensitive: A2 - Guideline
|
No biomarker
|
Nasopharyngeal Carcinoma
|
No biomarker
|
Nasopharyngeal Carcinoma
|
docetaxel Sensitive: A2 - Guideline
|
docetaxel Sensitive: A2 - Guideline
|
No biomarker
|
Nasopharyngeal Carcinoma
|
No biomarker
|
Nasopharyngeal Carcinoma
|
paclitaxel Sensitive: A2 - Guideline
|
paclitaxel Sensitive: A2 - Guideline
|
No biomarker
|
Nasopharyngeal Carcinoma
|
No biomarker
|
Nasopharyngeal Carcinoma
|
nedaplatin Sensitive: A2 - Guideline
|
nedaplatin Sensitive: A2 - Guideline
|
No biomarker
|
Nasopharyngeal Carcinoma
|
No biomarker
|
Nasopharyngeal Carcinoma
|
cisplatin Sensitive: A2 - Guideline
|
cisplatin Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Thyroid Gland Papillary Carcinoma
|
NTRK2 fusion
|
Thyroid Gland Papillary Carcinoma
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
TMB-H
|
Thyroid Gland Hurthle Cell Carcinoma
|
TMB-H
|
Thyroid Gland Hurthle Cell Carcinoma
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
No biomarker
|
Thyroid Gland Hurthle Cell Carcinoma
|
No biomarker
|
Thyroid Gland Hurthle Cell Carcinoma
|
denosumab Sensitive: A2 - Guideline
|
denosumab Sensitive: A2 - Guideline
|
No biomarker
|
Thyroid Gland Follicular Carcinoma
|
No biomarker
|
Thyroid Gland Follicular Carcinoma
|
denosumab Sensitive: A2 - Guideline
|
denosumab Sensitive: A2 - Guideline
|
TMB-H
|
Thyroid Gland Follicular Carcinoma
|
TMB-H
|
Thyroid Gland Follicular Carcinoma
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
